Mark Rothmann

Mark Rothmann

Auto-generated profile, based on publicly available information

Mark Rothmann

Department of Health and Human Services, Office of Biostatistics Center for Drug Evaluation and Research, FDA Silver Spring Maryland USA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2015 in Statistics in Biopharmaceutical Research
Verified
Journal Article
Closed access
MAMohamed Alosh
Mohamed Alosh
KFKathleen Fritsch
Kathleen Fritsch
MHMohammad Huque
Mohammad Huque
KMKooros Mahjoob
Kooros Mahjoob
GPGene Pennello
Gene Pennello
LYLilly Yue
Lilly Yue
The objective of subgroup analysis of a clinical trial is to investigate consistency or heterogeneity of the treatment effect across subgroups, defined based on background characteristics. As such, subgroup analysis plays an essential role in the interpretation of the clinical trial findings. Consistency of treatment effect across trial subgroups indicates that the average treatment effect is in general applicable regardless of the specific background characteristics. Substantial heterogeneity in treatment effect may be indicative that treatment benefit pertains only to a subset of the population. However, heterogeneity in the observed treatment effect across subgroups can arise due to chance as a result of partitioning the population into several subgroups. Furthermore, as it is known, clinical trials are generally not powered for detecting heterogeneity, thus statistical tests may miss detection of existing heterogeneity due to low power. In this article, we aim to: (i) outline the major issues underlying subgroup analysis in clinical trials and provide general statistical guidance for interpretation of its findings, (ii) provide statistical perspectives on the design and analysis of a clinical trial that aims for establishing efficacy in a targeted subgroup along with that of its overall population, and (iii) highlight some of the underlying assumptions and issues relevant to Bayesian subgroup analysis, subgroup considerations for noninferiority trials, personalized medicine, subgroup misclassification, and finally, subgroup analysis for safety assessment.

1 March 2012 in Drug Information Journal
Verified
Journal Article
Closed access
PDF file
MRMark D. Rothmann
Mark D. Rothmann
JZJenny J. Zhang
Jenny J. Zhang
LLLaura Lu
Laura Lu
TFThomas R. Fleming
Thomas R. Fleming

29 January 2023 in Journal of Biopharmaceutical Statistics
Verified
Journal Article
Closed access
JTJames Travis
James Travis
MRMark Rothmann
Mark Rothmann
ATAndrew Thomson
Andrew Thomson
Bayesian methods have been proposed as a natural fit for pediatric extrapolation, as they allow the incorporation of relevant external data to reduce the required sample size and hence trial burden for the pediatric patient population. In this paper we will discuss our experience and perspectives with these methods in pediatric trials. We will present some of the background and thinking underlying pediatric extrapolation and discuss the use of Bayesian methods within this context. We will present two recent case examples illustrating the value of a Bayesian approach in this setting and present perspectives on some of the issues that we have encountered in these and other cases.

23 November 2022 in Pharmaceutical Statistics
Verified
Journal Article
Closed access
RARobert Abugov
Robert Abugov
JCJennifer Clark
Jennifer Clark
LHLaura Higginbotham
Laura Higginbotham
FLFeng Li
Feng Li
LNLei Nie
Lei Nie
JSJohn Sharretts
John Sharretts

15 July 2024 in Pharmaceutical Statistics
Verified
Journal Article
Closed access
YWYun Wang
Yun Wang
WTWenda Tu
Wenda Tu
WKWilliam Koh
William Koh
JTJames Travis
James Travis
RARobert Abugov
Robert Abugov
MRMark Rothmann
Mark Rothmann

1 January 1998 in Journal of Nonparametric Statistics
Verified
Journal Article
Closed access
HBHammou El Barmi
Hammou El Barmi
MRMark Rothmann
Mark Rothmann
Consider two independent samples, one sample of size m from a distribution F and the other of size n from a weighted distribution G where with w(.)≤0 and Assume that there is a parameter θ∊R d associated with F through and consider the nonparametric estimators of F and of G on the basis of these two samples when θ is known and Φ is a real valued function and when θ is unknown and Φ is a rector valued function of dimension r<d. We show that converge weakly to pinned Gaussian processes as m+n goes to +∞ and m/n converges to a constant and provide the expressions of the covariance functions. In the case where θ is unknown and Φ is a vector valued function of dimension r<d, we propose an approximate chi-square test for testing θ = θ0 against all alternatives. This work is an extension of Vardi (1982a,b) and is closely connected to the work of Qin (1993) and Qin and Lawless (1995).